Cellanome
PrivateLast Round
Series B
Dec 23, 2025
Est. Valuation
$525M
Total Funding Raised
$217.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Cellanome operates in Healthcare & Life Sciences and is based in Foster City, California. Its latest recorded funding round was a Series B round in January 2024.
Cellanome is a biotechnology company that develops an integrated multi-omics platform for high-resolution, large-scale biological measurement and live-cell analysis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cellanome Comparables
Compare Cellanome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mission Bio | 79% | |
| Singleron Biotechnologies | 77% | |
| Neomend | 75% |
For institutional investors. Book with your work email.
Cellanome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 23, 2025 | ||||
| Series B | Jan 29, 2024 | ||||
| Series A | Mar 21, 2023 | ||||
| Seed | Oct 5, 2021 | ||||
| Series A | Jul 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cellanome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Angel | Series B, Seed, Series A |
| Khosla Ventures | Series A |
| RONA Holdings | Series A, Seed |
| Wing Venture Capital | Series B, Seed, Series A |
| DFJ Growth | Seed, Series A, Series B |
| Premji Invest | Series B, Seed, Series A |
| 8VC | Series B, Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2026
Hiring for Director of Product Management for the Cellanome R3200 platform.
- Dec 23, 2025
Raised $76M in Series B funding.
For institutional investors. Book with your work email.
Cellanome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cellanome's valuation, stock price, and market status.
Is Cellanome a public or private company?
Cellanome is a private company.
What is the current stock price of Cellanome?
Cellanome is a private company, so its shares have no public market price. Caplight tracks Cellanome's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cellanome worth (valuation)?
Cellanome's valuation is estimated at $525.0M based on funding round data.
Can I buy Cellanome stock?
Cellanome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cellanome's last funding round?
Cellanome's most recent funding round was Series B on December 23, 2025.
Who are the main investors in Cellanome?
Key investors in Cellanome include Khosla Ventures, DFJ Growth, DCVC (Data Collective).
Will Cellanome IPO soon?
No public IPO plans have been announced for Cellanome.
How can I track Cellanome secondary market activity?
Caplight tracks bids, offers, and trades in Cellanome's shares on secondary markets.